Cendakimab is a humanized monoclonal antibody directed against IL-13. Cendakimab targets IL-13 and inhibits its binding to both IL-13-receptor specific subtypes (IL-13-R_1 and IL-13-R_2). Cendakimab has been used in the research of eosinophilic esophagitis.